BAX vs. PODD, TFX, RMD, GMED, DXCM, BDX, BSX, WST, PEN, and SWAV
Should you be buying Baxter International stock or one of its competitors? The main competitors of Baxter International include Insulet (PODD), Teleflex (TFX), ResMed (RMD), Globus Medical (GMED), DexCom (DXCM), Becton, Dickinson and (BDX), Boston Scientific (BSX), West Pharmaceutical Services (WST), Penumbra (PEN), and Shockwave Medical (SWAV). These companies are all part of the "surgical & medical instruments" industry.
Baxter International vs.
Baxter International (NYSE:BAX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
84.8% of Baxter International shares are held by institutional investors. 0.3% of Baxter International shares are held by insiders. Comparatively, 0.8% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Insulet has lower revenue, but higher earnings than Baxter International.
In the previous week, Insulet had 3 more articles in the media than Baxter International. MarketBeat recorded 12 mentions for Insulet and 9 mentions for Baxter International. Insulet's average media sentiment score of 0.78 beat Baxter International's score of 0.36 indicating that Insulet is being referred to more favorably in the news media.
Baxter International has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
Baxter International received 28 more outperform votes than Insulet when rated by MarketBeat users. Likewise, 67.16% of users gave Baxter International an outperform vote while only 66.48% of users gave Insulet an outperform vote.
Insulet has a net margin of 0.04% compared to Baxter International's net margin of -16.34%. Baxter International's return on equity of 24.29% beat Insulet's return on equity.
Baxter International currently has a consensus target price of $52.38, indicating a potential upside of 28.62%. Insulet has a consensus target price of $330.00, indicating a potential upside of 20.33%. Given Baxter International's higher possible upside, analysts clearly believe Baxter International is more favorable than Insulet.
Summary
Insulet beats Baxter International on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Baxter International Competitors List
Related Companies and Tools